Articles published by Optinose, Inc.
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
March 07, 2024
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
December 06, 2023
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose to Present at the 2023 Cantor Global Healthcare Conference
September 22, 2023
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
July 27, 2023
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Announces CEO Transition and Business Update
January 31, 2023
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Appoints Paul Spence as Chief Commercial Officer
December 15, 2022
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Announces Departure of Acting Chief Financial Officer
December 09, 2022
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
November 30, 2022
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Optinose Announces Proposed Public Offering of Common Stock and Warrants
November 21, 2022
From Optinose, Inc.
Via GlobeNewswire
Tickers
OPTN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.